Effect of Dingkundan in Treatment of Qi Stagnation and Blood Stasis Syndrome in Patients with Chronic Obstructive Pulmonary Disease at Stable Phase
10.13422/j.cnki.syfjx.20241695
- VernacularTitle:定坤丹治疗慢性阻塞性肺疾病稳定期气滞血瘀型患者评价
- Author:
Yanyi LIU
1
;
Zhaoquan YANG
2
;
Jiang MA
3
;
Kun XIA
1
;
Xiaoyan YAO
1
;
Guangxi LI
1
Author Information
1. Guang'anmen Hospital, China Academy of Chinese Medical Sciences,Beijing 100053,China
2. Shanghai Fengxian District Traditional Chinese Medicine Hospital,Shanghai 201499,China
3. Beijing Xicheng District Guangwai Hospital,Beijing 100055,China
- Publication Type:Journal Article
- Keywords:
Dingkundan;
chronic obstructive pulmonary disease （COPD）;
stable phase;
Qi stagnation and blood stasis syndrome;
randomized controlled trial;
clinical effectiveness
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(13):128-134
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the effect of Dingkundan on Qi stagnation and blood stasis syndrome in patients with chronic obstructive pulmonary disease （COPD） at a stable phase. MethodA randomized controlled clinical design method was adopted， and 60 patients who were diagnosed with Qi stagnation and blood stasis syndrome in COPD at a stable phase in the outpatient and inpatient departments of the respiratory department of Guang' anmen Hospital of China Academy of Chinese Medical Sciences from June 2019 to December 2019 were divided into observation group and control group according to 1∶1. During the study period， there was no dropout， loss of follow-up， or exclusion between the two groups. On the basis of both groups receiving traditional Chinese medicine （TCM） lung rehabilitation training， the observation group took Dingkundan 7 g/time orally， twice a day. The control group received oral administration of the same specification of Dingkundan starch simulator of 7 g/time， twice a day. Both groups have a treatment period of 12 weeks. The COPD Assessment Test （CAT）， modified Medical Research Council （mMRC）， fatigue scale-14 （FS-14）， self-rating anxiety scale （SAS）， self-rating depression scale （SDS）， 6-minute walk distance （6MWD）， and pulmonary function before and after treatment were evaluated. ResultAfter treatment， both groups showed improvements in CAT， mMRC， FS-14， SAS scores， and 6MWD （P<0.05）. The observation group also showed improvements in SDS scores and lung function indicators （P<0.05）. Compared with the control group after treatment， the observation group showed more significant improvement in CAT， FS-14， SAS， SDS scores， and 6MWD （P<0.05）. ConclusionDingkundan has a clear therapeutic effect on Qi stagnation and blood stasis syndrome in patients with COPD at a stable phase. It can reduce symptom burden， enhance exercise capacity， and improve psychological status and has the potential to improve lung function.
